AU2021286582A1 - TLR7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus - Google Patents

TLR7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus Download PDF

Info

Publication number
AU2021286582A1
AU2021286582A1 AU2021286582A AU2021286582A AU2021286582A1 AU 2021286582 A1 AU2021286582 A1 AU 2021286582A1 AU 2021286582 A AU2021286582 A AU 2021286582A AU 2021286582 A AU2021286582 A AU 2021286582A AU 2021286582 A1 AU2021286582 A1 AU 2021286582A1
Authority
AU
Australia
Prior art keywords
compound
prednisolone
hydroxychloroquine
therapeutically effective
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021286582A
Other languages
English (en)
Inventor
Shailesh DUDHGAONKAR
Gary L. Schieven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2021286582A1 publication Critical patent/AU2021286582A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021286582A 2020-06-11 2021-06-10 TLR7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus Pending AU2021286582A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202011024586 2020-06-11
IN202011024586 2020-06-11
PCT/US2021/036740 WO2021252718A1 (en) 2020-06-11 2021-06-10 Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus

Publications (1)

Publication Number Publication Date
AU2021286582A1 true AU2021286582A1 (en) 2023-02-09

Family

ID=76959055

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021286582A Pending AU2021286582A1 (en) 2020-06-11 2021-06-10 TLR7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus

Country Status (11)

Country Link
US (1) US20230310408A1 (https=)
EP (1) EP4164639A1 (https=)
JP (2) JP7751597B2 (https=)
KR (1) KR20230023717A (https=)
CN (1) CN115701995A (https=)
AU (1) AU2021286582A1 (https=)
BR (1) BR112022024999A2 (https=)
CA (1) CA3181964A1 (https=)
IL (1) IL298667A (https=)
MX (1) MX2022015760A (https=)
WO (1) WO2021252718A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
AU2024356361A1 (en) * 2023-10-02 2026-04-02 Bristol-Myers Squibb Company A method of treating lupus
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270707A1 (en) 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
EP2582398B1 (en) * 2010-06-16 2016-04-13 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
AU2013203815A1 (en) * 2010-06-16 2013-05-02 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
WO2015200094A1 (en) * 2014-06-20 2015-12-30 Baylor Research Institute Methods and compositions for systemic lupus erythematosus (sle) therapy
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Also Published As

Publication number Publication date
US20230310408A1 (en) 2023-10-05
JP7751597B2 (ja) 2025-10-08
BR112022024999A2 (pt) 2022-12-27
KR20230023717A (ko) 2023-02-17
WO2021252718A1 (en) 2021-12-16
EP4164639A1 (en) 2023-04-19
MX2022015760A (es) 2023-01-19
JP2025183420A (ja) 2025-12-16
CN115701995A (zh) 2023-02-14
JP2023530264A (ja) 2023-07-14
CA3181964A1 (en) 2021-12-16
IL298667A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
US20230310408A1 (en) Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus
EP3206682B1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
EP3922246A1 (en) Cenicriviroc for the treatment of fibrosis
JP7564347B2 (ja) 多発性硬化症を治療するためのｌｏｕ０６４
TW200423932A (en) Combination of a PDE IV inhibitor and a TNF-alpha antagonist
US20230310409A1 (en) Treating rheumatoid arthritis
AU2015231076B2 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
WO2009019473A1 (en) Treatments for inflammatory arthritis
US20100273750A1 (en) Serotonin receptor antagonists for treating arthritis
EA048070B1 (ru) Способы лечения кожной красной волчанки
US20210236594A1 (en) Methods for improving frailty and aging
US20230019602A1 (en) Methods for treatment of motor neuron diseases
EP4230196A1 (en) Compounds for use in the treatment of dystrophinopathies
JP2026049047A (ja) 変形性膝関節症および肩関節周囲炎の疼痛改善剤
WO2025248468A1 (en) Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
CN118019540A (zh) 用于治疗多发性硬化的lou064
WO2025075944A1 (en) A method of treating lupus
TW202539703A (zh) 治療多囊性腎病之方法